1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 17,000 | 17,200 | 23.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | DUALITYBIO-B Repurchased 30,000 Shares Yesterday for Nearly HKD4.83 million | 5 | AASTOCKS | ||
| 14.10. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 28.09. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.09. | DUALITYBIO-B (09606): 2026 INTERIM REPORT | 2 | HKEx | ||
| 28.08. | DualityBio and Genentech to Develop Next-Gen ADCs on Novel Payload Platform | 7 | Contract Pharma | ||
| 28.08. | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 28.08. | Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact | 14 | FierceBiotech | ||
| 28.08. | DualityBio partners with Genentech on cancer drug development | 24 | Investing.com | ||
| 28.08. | DualityBio und Genentech schließen milliardenschweren Pakt zur Entwicklung von Krebsmedikamenten | 25 | Investing.com Deutsch | ||
| 28.08. | Duality Biotherapeutics Inc.: DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform | 737 | PR Newswire | Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical... ► Artikel lesen | |
| 28.08. | DUALITYBIO-B (09606): INSIDE INFORMATION - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH, INC. TO DEVELOP NEXT-GENERATION ... | 1 | HKEx | ||
| 14.08. | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 7 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): (1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES ... | 6 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): GRANT OF RESTRICTED SHARE UNITS UNDER THE 2025 SHARE SCHEME | 1 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 12.06. | DUALITYBIO-B (09606): ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE | 2 | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB ... | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2026 | 1 | HKEx |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,85 | +0,19 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Moderna leaked data was positive, what's hurting MRNA stock then? | ||
| PALATIN TECHNOLOGIES | 5,110 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,247 | +1,23 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| QIAGEN | 45,050 | +0,26 % | EQS-WpÜG: Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V. | EQS-WpÜG: Crown NL Bidco B.V. / Übernahmeangebot
Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V.
21.10.2026 / 23:30 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,360 | +0,09 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| COGENT BIOSCIENCES | 31,210 | 0,00 % | If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| SUMMIT THERAPEUTICS | 15,470 | 0,00 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,73 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,200 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| PRAXIS PRECISION MEDICINES | 252,88 | -0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 21,010 | +0,05 % | ArriVent to present phase 1 data for ARR-217 at ESMO | ||
| BOLT BIOTHERAPEUTICS | 6,250 | -0,32 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| TRAVERE THERAPEUTICS | 50,05 | 0,00 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen |
DUALITY BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 17,200 Euro und damit -10,88 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.